Related Experiment Video
Updated: Jun 12, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Thrombosis in children with hematologic malignancies
Rosemarie Schobess1, Beate Kempf-Bielack, Dirk Schwabe
1Department of Pediatrics, University of Halle, Germany.
Insights
Pediatric acute lymphoblastic leukemia patients with prothrombotic risk factors may develop venous thrombosis due to prednisone and E. coli asparaginase treatment. Preventive anticoagulant strategies are discussed.
Area of Science:
- Pediatric Hematology
- Oncology
- Thrombosis Research
Background:
- Symptomatic thrombosis is a concern in children with hematologic malignancies.
- Acquired and inherited prothrombotic risk factors increase this risk.
- Treatment protocols, including chemotherapy, interact with these risk factors.
Purpose of the Study:
- To review pediatric reports on thrombosis in children with hematologic malignancies.
- To discuss the interplay of treatment, risk factors, and thrombosis.
- To suggest potential preventive strategies for thrombosis.
Main Methods:
- Literature review of pediatric reports up to January 2004.
- Analysis of symptomatic thrombosis cases in children with hematologic malignancies, primarily acute lymphoblastic leukemia.
- Discussion of various prothrombotic risk factors (genetic and acquired) and treatment modalities.
Main Results:
- Prednisone and E. coli asparaginase administered together appear to be a significant factor in venous thrombosis onset in leukemic patients with prothrombotic risk factors.
- Interactions between treatment, study design, ethnicity, and central venous catheters are considered.
- The review highlights the complexity of thrombosis development in this patient population.
Conclusions:
- Concomitant administration of prednisone and E. coli asparaginase is implicated in the majority of venous thrombosis cases in pediatric leukemia patients with prothrombotic risk factors.
- Primary preventive anticoagulant or antithrombotic strategies should be considered.
- Further research into risk stratification and tailored preventive measures is warranted.
Abstract:
This review is based on pediatric reports (- January 2004) on the presence of symptomatic thrombosis in children with hematologic malignancies, mainly acute lymphoblastic leukemia, treated with different treatment protocols and associated with acquired and inherited prothrombotic risk factors (factor V G1691A, factor G20210A, MTHFR C677T genotypes, protein C, protein S, antithrombin, elevated levels of lipoprotein(a), and homocysteine). The interactions of treatment modalities, study designs, ethnical backgrounds and associated central lines are discussed. Based on the data presented here, we suggest the use of prednisone and E. coli asparaginase concomitantly administered in a leukemic patient suffering a prothrombotic risk factor to be responsible for the onset of venous thrombosis in the majority of cases. In addition, primary preventive anticoagulant/antithrombotic strategies are discussed.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

